Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 32 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma September 26, 2023 No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... November 17, 2025 Workout Wednesdays – Chest Exercises Part 2 June 17, 2020 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia July 30, 2021 Load more HOT NEWS FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated... Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... Grace and Love for Full Hands ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges...
